Abstract
Several different meningococcal outer membrane protein vaccines have been prepared and used in human safety and immunogenicity studies. The results of these studies have led to some general conclusions regarding the human antibody response to these vaccines. A review of these conclusions, however, indicates that a number of important questions and problems still need to be addressed. Two of these are the determination of the protective level of bactericidal antibody in human serum and the impact of phase variation of surface antigens on vaccine strategy. Bactericidal assays using intrinsic complement and high concentrations of serum suggest that the level of natural immunity to group B meningococci is quite high, but is increased by vaccination with outer membrane protein vaccine. Phase variation in meningococcal surface antigens including capsule, class 1 protein, class 5 protein, and lipopolysaccharide was demonstrated using colony blotting with monoclonal antibodies. Phase variation resulted in differences in susceptibility to the bactericidal activity of human sera.
Similar content being viewed by others
References
Frasch, C. E., G. Goetzee, J. M. Zahradnik & L. Y. Wang (1985) New developments in meningococcal vaccines. In: G. K. Schoolnik (Ed) The Pathogenic Neisseriae (pp. 633–639). Amer. Assoc. for Microbiol., Washington, D.C.
Frasch, C. E. & J. M. Zahradnik (1986) Human immune response to an aluminum hydroxide absorbed Neisseria meningitidis serotype 2b protein vaccine. Antonie van Leeuwenhoek 52: 229–231
Frøholm, L. O., B. P. Berdal, K. Bovre, P. Gaustad, A. I. Halstensen, A. Harboe, S. Harthug, E. Holten, E. A. Hoiby, A. Lystad, T. Omland, E. Rosenqvist, G. Viko, C. E. Frasch & W. D. Zollinger (1986) Preliminary results from a clinical trial with meningococcal vaccine containing serotype 2b and 15 antigens in complex with mixed A, C, Y, and W135 polysaccharides. Antonie van Leeuwenhoek 52: 239–241
Gotschlich, E. C., B. A. Fraser, O. Nishimura, J. B. Robbins & T-Y Liu (1981) Lipid on capsular polysaccharides of gram-negative bacteria. J. Biol. Chem. 256: 8915–8921
Masson, L., B. E. Holbein & F. E. Ashton (1982) Virulence linked to polysaccharide production on serogroup B Neisseria meningitidis. FEMS Microbiol. Let. 13: 187–190
Poolman, J. T., C. T. P. Hopman & H. C. Zanen (1985) Colony variants of Neisseria meningitidis strain 2996 (B:2b:P1.2): Influence of class-5 outer membrane proteins and lipopolysaccharides. J. Med. Microbiol. 19: 203–209
Zollinger, W. D., B. L. Brandt & E. C. Tramont (1986a) Immune response to Neisseria meningitidis. In: N. R. Rose & H. Friedman (Ed) Manual of Clinical Immunology. 3rd edn (p. 346). American Society for Microbiology, Washington, D.C.
Zollinger, W. D., J. W. Boslego, B. Brandt, E. E. Moran & J. Ray (1986b) Safety and antigenicity studies of a polyvalent meningococcal protein-polysaccharide vaccine. Antonie van Leeuwenhoek 52: 225–228
Zollinger, W. D., J. Boslego, E. Moran, B. Brandt, H. Collins, R. Mandrell, P. Altieri & S. Berman (1985) Bactericidal antibody response to a polyvalent meningococcal protein-polysaccharide vaccine. In: J. B. Robbins et al. (Eds) Bacterial Vaccines Symposium. NIH. Sept. 1984 (Submitted for publication)
Zollinger, W. D. & R. E. Mandrell (1983) Importance of complement source in bactericidal activity of human antibody and murine monoclonal antibody to meningococci. Infect. Immun. 40: 257–264
Zollinger, W. D., R. E. Mandrell & J. M. Griffiss (1980) Enhancement of immunological activity by noncovalent complexing of meningoococcal group B polysaccharide and outer membrane proteins. In: J. B. Robbins, J. C. Hill & J. V. Sadoff (Eds) Seminars in Infectious Disease. Vol. IV, Bacterial vaccines (pp. 254–262) Thieme-Stratton Inc., New York
Zollinger, W. D., R. E. Mandrell, J. M. Griffiss, P. Altieri & S. Berman (1979) A complex of meningococcal group B polysaccharide and type 2 outer membrane protein immunogenic in man. J. Clin. Invest. 63: 836–848
Zollinger, W. D., E. E. Moran, H. Connelly, R. E. Mandrell & B. Brandt (1984) Monoclonal antibodies to serotype 2 and serotype 15 outer membrane proteins of Neisseria meningitidis and their use in serotyping. Infect. Immun. 46: 260–266
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Zollinger, W.D., Boslego, J., Frøholm, L.O. et al. Human bactericidal antibody response to meningococcal outer membrane protein vaccines. Antonie van Leeuwenhoek 53, 403–411 (1987). https://doi.org/10.1007/BF00415494
Issue Date:
DOI: https://doi.org/10.1007/BF00415494